Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


Researchers at the University of Geneva (UNIGE), Switzerland, and Geneva University Hospitals (HUG) have identified a DNA-binding factor called TOX that might play a role in triggering multiple...

In December 2017 the National Institute of Health and Care Excellence (NICE) announced a...

The US Food and Drug Administration has approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval...

According to a French study, the approved cancer drug rituximab, which...

A new study, published in the May issue of Journal of Clinical Investigation, has...

According to a recent study, published at the 2018 AAN Annual Meeting in Los Angeles,...

US neurologists have reported the highest self-reported disease modifying therapy (DMT) switch rates in the US in the past three months. Active secondary progressive multiple sclerosis (SPMS) and...

Pages

Live Chat Software by Click4Assistance UK